Clinical Trial

Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma

Name: Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma — clinical trial record (NCT07369895)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\&D-001 injection in the treatment of relapsed or refractory multiple myeloma.

Trial Details

NCT Number	NCT07369895
Lead Sponsor	O&D BioTech Group CO., Limited
Conditions	Relapsed or Refractory Multiple Myeloma
Enrollment	18 participants
Start Date	2025-10-28
Primary Completion	2028-03-28 (estimated)
Study Completion	2028-03-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-27